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Abstract
Background: Hepatocarcinogenesis is a complex process that may be influenced by many factors, including polymorphism
in the epidermal growth factor (EGF) gene. Previous work suggests an association between the EGF 61*A/G polymorphism
(rs4444903) and susceptibility to hepatocellular carcinoma (HCC), but the results have been inconsistent. Therefore, we
performed a meta-analysis of several studies covering a large population to address this controversy.
Methods: PubMed, EMBASE, Google Scholar and the Chinese National Knowledge Infrastructure databases were
systematically searched to identify relevant studies. Data were abstracted independently by two reviewers. A meta-analysis
was performed to examine the association between EGF 61*A/G polymorphism and susceptibility to HCC. Odds ratios (ORs)
and 95% confidence intervals (95% CIs) were calculated.
Results: Eight studies were chosen in this meta-analysis, involving 1,304 HCC cases (1135 Chinese, 44 Caucasian and 125
mixed) and 2,613 controls (1638 Chinese, 77 Caucasian and 898 mixed). The EGF 61*G allele was significantly associated with
increased risk of HCC based on allelic contrast (OR=1.29, 95% CI=1.16–1.44, p,0.001), homozygote comparison (OR=1.79,
95% CI=1.39–2.29, p,0.001) and a recessive genetic model (OR=1.34, 95% CI=1.16–1.54, p,0.001), while patients
carrying the EGF 61*A/A genotype had significantly lower risk of HCC than those with the G/A or G/G genotype (A/A vs. G/
A+G/G, OR=0.66, 95% CI=0.53–0.83, p,0.001).
Conclusion: The 61*G polymorphism in EGF is a risk factor for hepatocarcinogenesis while the EGF 61*A allele is a protective
factor. Further large and well-designed studies are needed to confirm this conclusion.
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Introduction
As the most frequent primary cancer of the liver, hepatocellular
carcinoma (HCC) is the fifth most common solid tumor worldwide
and the third leading cause of cancer-related deaths, exceeded
only by lung cancer and gastric cancer [1]. The estimated
incidence of new HCC cases each year is approximately 500 000–
1 000 000, and it causes 600 000 deaths globally each year [1]. In
fact, the number of HCC-related deaths nearly equals the number
of cases diagnosed each year [2]. The highest incidence rates of
HCC (.20 per 100,000) were reported from countries in sub-
Saharan Africa and Southeast Asia [2]. Cirrhosis, particularly
when it is related to infection by hepatitis C virus (HCV) and/or
hepatitis B virus (HBV), is the strongest known risk factor for HCC
[3–4]. The pathogenesis of HCC may involve chronic inflamma-
tion, hepatocyte hyperplasia and ultimately malignant transfor-
mation [5]. HCC exhibits a high degree of genetic heterogeneity:
multiple molecular pathways may give rise to subsets of
hepatocellular neoplasms [5]. For this reason, HCC pathogenesis
remains incompletely understood.
Most diagnoses of HCC are made after the disease has
progressed substantially. In addition, current therapies for HCC
are ineffective for most patients. Consequently, effective screening
and chemoprevention depend on early identification of high-risk
populations [6]. Traditionally, serum alpha fetoprotein measure-
ment and liver imaging have been the two main strategies for
screening high-risk populations. However, both techniques have
low sensitivity and specificity, limiting their effectiveness [7–9]. For
this reason, identification of molecular markers associated with
increased risk of HCC would better define high-risk populations of
HCC, helping to improve prevention and treatment strategies.
Epidermal growth factor (EGF) has many biological functions
involving stimulation of proliferation, differentiation and tumor-
igenesis of epidermal and epithelial tissues [10–11]. EGF is a
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expression is up-regulated during liver regeneration [12]. In recent
years, numerous studies have associated a single-nucleotide
polymorphism involving an A-to-G mutation at position 61 of
the 59 untranslated region of the EGF gene (61*A/G, rs4444903)
with the risk of tumorigenesis in multiple human cancers [13–15].
This polymorphism modulates tissue-specific EGF gene expres-
sion.
In 2008, Tanabe and coworkers [16] explored the association
between EGF polymorphism and risk of HCC. They found that
the EGF gene polymorphism 61*A/G is associated with risk of
developing HCC. Subsequently, epidemiological studies have
evaluated the association between the EGF gene polymorphism
61*A/G and risk of HCC in diverse ethnicities [17–21]. However,
the results have been inconsistent. Some studies have indicated
that patients carrying G/G genotypes have a higher susceptibility
to HCC [16–17], while other studies have not [18–20]. A single
case-control study may fail to completely demonstrate this
complicated genetic relationship because of small sample size. In
order to provide strong evidence of the effects of this EGF
polymorphism on HCC risk, we carried out a meta-analysis by
combining data from numerous published studies.
Materials and Methods
Search strategy
All case-control studies of EGF polymorphism and HCC risk
published up to October 1, 2011 were identified through
systematic searches in PubMed, EMBASE, Google Scholar and
the Chinese National Knowledge Infrastructure (CNKI) databases
using English and Chinese. The search terms used were: EGF;
epidermal growth factor; these two terms in combination with
polymorphism, variation, genotype, genetic and mutation; and all of the
above terms in combination with hepatocellular carcinoma, HCC, liver
cancer, liver tumor, liver neoplasms and hepatic tumor. For each article
identified, manual search of the relevant references was also
performed.
Inclusion criteria
A study was included in the meta-analysis if it satisfied the
following criteria: (a) it assessed the correlation between HCC and
the EGF 61*A/G polymorphism, (b) it used a case-control design,
and (c) it provided sufficient published data for estimating an odds
ratio (OR) with a 95% confidence interval (95% CI). In the case of
multiple studies with the same or overlapping data published by
the same researchers, we selected the most recent study with the
largest number of participants.
Data extraction
Literature searches and identification of eligible articles based
on the inclusion criteria were carried out independently by two
authors (JHZ and XMY). Then each of these authors indepen-
dently extracted data about the first author’s name; year of
publication; country of origin; ethnicity, numbers and genotypes of
cases and controls; source of controls (hospital- or population-
based); frequency of G allele; genotyping method; and Hardy-
Weinberg equilibrium (HWE) of controls. Discrepancies were
resolved by consensus.
Statistical methods
The unadjusted OR with 95% CI was used to assess the strength
of the association between the EGF 61*A/G polymorphism and
HCC based on the genotype frequencies in cases and controls.
Subgroup analysis stratified by ethnicity was performed. Ethnicity
was categorized as Chinese, mixed or Caucasian. The meta-analysis
examined the association of different genotypes at EGF 61*A/G
(rs4444903) with HCC risk by comparing the G allele and the A
allele(G-allelevs.A-allele),thehomozygous genotypes G/G andA/
A (G/G vs. A/A), the homozygous genotype (G/G) and recessive
genotypes A/A and G/A (G/G vs. A/A+G/A), and the dominant
genotype A/A and G/G+G/A (A/A vs. G/G+G/A).
Fixed-effect and random-effect models were used to calculate a
pooled OR. The statistical significance of the pooled OR was
determined by the Z-test, and P,0.05 was considered statistically
significant. The assumption of heterogeneity was evaluated by
applying a chi square-based Q-test among the studies. In this
approach, the Q value is defined to be identical to the effect size of
the chi square. A P value more than 0.10 for the Q-test indicated a
lack of heterogeneity, in which case a pooled OR was calculated
for each study using the fixed-effects model. Otherwise, the
random-effects model was used. Publication bias was assessed by
visual inspection of Begg’s funnel plots. An asymmetric plot
suggested possible publication bias, in which case Egger’s test [22]
was used. HWE in the control group was assessed using Fisher’s
exact test, with P,0.05 considered significant. All statistical tests
for this meta-analysis were performed using RevMan 5.0 software.
Results
Description of studies
A total of 287 potentially relevant publications up to October 1,
2011 were systematically identified through PubMed, EMBASE,
Google Scholar and CNKI. Of these, 258 (90%) were excluded
because they did not satisfy the inclusion criteria, or they failed to
provide sufficient information to determine whether the criteria
were satisfied. An additional 23 publications were excluded because
they did not examine the EGF 61*A/G polymorphism or they were
review articles. Two articles reporting a relationship between the
EGF 61*A/G polymorphism and chronic hepatitis C [23–24] were
also excluded, because the participants in these two articles did not
have HCC. The article by Kovar et al. [25] investigated the
influence of the EGF 61*A/G polymorphism on the recurrence of
liver metastases in patients with colorectal cancer and was excluded.
Two publications [20,26] had the same first author and were based
on the same participants with HCC, so they were considered as one
study. The articles by Tanabe et al. [16] and Wang et al. [21] each
involved two independent case-control studies and were considered
separately, giving 4 studies altogether. In the end, 8 studies [16–21]
wereincluded inthis meta-analysis based on oursearchstrategy and
inclusion criteria (Fig. 1).
We established a database according to the information
extracted from each article. Detailed characteristics of the 8
studies are listed in Table 1. Overall, 1,304 HCC cases and 2,613
controls were retrieved. Five of the studies involved Chinese
subjects [18–21], two involved mixed populations (White, Black,
Hispanic, Asian and other) [16–17] and one involved Caucasians
[16]. All studies had a case-control design, and three [18–20]
included a healthy control population (population-based control).
These three studies [18–20] involved 521 HCC cases and 514
controls. The number of cases in the hospital-based control was
2,099. Of the total number of 3,917 subjects considered in the
meta-analysis, 3,403 (86.9%) were with cirrhosis and/or infected
with hepatitis B virus. The distribution of genotypes among
controls showed HWE in all the studies.
Test of heterogeneity
Table S1 shows the relationship between the EGF 61*A/G
polymorphism and HCC risk. The heterogeneity of EGF 61*A/G
EGF 61*A/G and HCC Risk
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recessive genetic models was analyzed for all 8 studies. Random-
effect models were used to analyze the OR for the mixed
population (G-allele vs. A-allele, G/G vs. A/A, G/G+G/A vs. A/
A). Fixed-effect models were used to analyze the OR for the other
populations.
Quantitative data synthesis
Table S1 shows the summary ORs for the EGF 61*A/G
polymorphism and HCC risk on the basis of 1,304 HCC cases and
2,613 controls. We observed an association between EGF
genotype and HCC risk in the total population based on all 8
studies. Given the ethnic differences in the allele frequency of this
sequence variant, we evaluated the effect of EGF 61*A/G
polymorphism in Chinese, mixed and Caucasian populations
separately. We also evaluated the summary ORs stratified by
source of control (hospital- or population-based).
Total population
Calculation of overall OR in the total population using the
fixed-effect model showed that the 61*G allele was strongly
associated with increased risk of HCC in allelic contrast
(OR=1.29, 95% CI=1.16–1.44, P,0.001; I
2=20%), homozy-
gote comparison (OR=1.79, 95% CI=1.39–2.29, P,0.001;
I
2=0%) and the recessive genetic model (OR=1.34, 95%
CI=1.16–1.54, P,0.001; I
2=36%) (Fig. 2. a). Association of
the EGF 61*A/A genotype with decreased HCC risk was observed
in the total population in the dominant genetic model (OR=0.66,
95% CI=0.53–0.83, P,0.001; I
2=0%) (Fig. 2. b).
Sensitivity analysis showed that similar results were obtained
when a random-effect model was used.
Ethnicity
Chinese population. After stratification for ethnicity, we
observed that in the Chinese population, the G-allele, homozygote
variant (G/G) and recessive genetic model were significantly
associated with increased risk of HCC (G-allele, OR=1.22, 95%
CI=1.08–1.37, P=0.001; G/G, OR=1.58, 95% CI=1.17–2.12,
P=0.002; recessive model, OR=1.25, 95% CI=1.07–1.45,
P=0.005). However, this association was not observed in the
dominant genetic model (OR=0.69, 95% CI=0.52–0.92,
P=0.01).
Mixed population. Analysis of the mixed population in two
studies revealed that the G-allele, homozygote variant (G/G) and
recessive genetic model were significantly associated with
increased risk of HCC using a fixed-effect model (G-allele,
OR=1.67, 95% CI=1.10–2.52, P=0.01; G/G, OR=2.51,
95% CI=1.09–5.78, P=0.03; recessive model, OR=2.00, 95%
CI=1.33–3.01, P,0.001). However, the dominant EGF genotype
was not associated with HCC risk in these two studies.
Caucasian population. The EGF 61*A/G polymorphism
was associated with increased risk of HCC among Caucasians (G-
allele vs. A-allele, OR=1.75, 95% CI=1.03–2.97, P=0.04; G/G
Table 1. Main characteristics of all studies included in the meta-analysis.
Study Ethnicity
Genotyping
method
Source of
control PHWE
Frequency
of G allele Cases/Controls No. of cases No. of controls
GG GA AA GG GA AA
Tanabe 2008a
16 Mixed PCR-RFLP HB 0.19 0.001 59/148 23 27 9 32 65 51
Tanabe 2008b
16 Caucasian PCR-RFLP HB 0.99 0.04 44/77 15 17 12 12 37 28
Abu 2011
17 Mixed allele-specific PCR HB 0.08 0.08 66/750 24 25 17 180 350 220
Chen 2011
18 Chinese-Han PCR-RFLP HB and PB 0.56 0.11 120/240 62 51 7 106 110 24
Li 2009
19 Chinese-Han PCR-RFLP HB and PB 0.94 0.12 186/338 96 82 8 161 145 32
Qi 2009
20 Chinese-Han PCR-RFLP HB and PB 0.75 0.55 215/380 102 98 15 182 160 38
Wang 2009a
21 Chinese* PCR-RFLP HB 0.37 0.06 397/480 200 163 34 209 222 49
Wang 2009b
21 Chinese-Han PCR-RFLP HB 0.53 0.06 217/200 125 76 16 94 89 17
Abbreviations: PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; PB, population-based; HB, hospital-based; PHWE, Hardy-Weinberg
equilibrium of controls.
*Included multiple ethnicities in China.
doi:10.1371/journal.pone.0032159.t001
Figure 1. Flow chart of study selection. EGF, epidermal growth
factor; HCC, hepatocellular carcinoma.
doi:10.1371/journal.pone.0032159.g001
EGF 61*A/G and HCC Risk
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model, OR=2.80, 95% CI=1.17–6.73, P=0.02). However, the
dominant genetic model was not associated with significantly
lower HCC risk among Caucasians (OR=0.66, 95% CI=0.29–
1.47, P=0.31).
Source of control
Hospital-based control. Overall, the variant genotypes G/
G+G/A of EGF 61*A/G were associated with significantly higher
HCC risk than was the A/A genotype (G/G vs. A/A, OR=1.87,
95% CI=1.45–2.42, P,0.001; recessive model, OR=1.47, 95%
CI=1.26–1.71, P,0.001). We also found that the frequency of the
G allele was strongly associated with increased risk of HCC in
allelic contrast (OR=1.36, 95% CI=1.21–1.52, P,0.001).
Population-based control. When comparing population-
based controls, we observed an association between the
polymorphism and decreased HCC risk in the dominant genetic
model (OR=0.61, 95% CI=0.38–0.97, P=0.04). Interestingly,
the polymorphism was not associated with significantly increased
risk in allelic contrast (OR=1.06, 95% CI=0.88–1.29, P=0.52),
homozygote comparison (OR=1.56, 95% CI=0.96–2.55,
P=0.07) or the recessive genetic model (OR=0.97, 95%
CI=0.76–1.23, P=0.78).
Publication bias
Begg’s funnel plots were prepared and Egger’s test was
performed on the final set of 8 studies [16–21] to assess publication
bias for reported comparisons of 61*A/G genotypes and HCC.
The shape of the funnel plots (Fig. 3) seemed asymmetrical for the
comparison of different alleles of the EGF 61*A/G polymorphism,
suggesting the presence of publication bias. Therefore, Egger’s test
was performed to assess funnel plot symmetry statistically. No
evidence of publication bias was found for comparisons of EGF
61* A/A with G/G+G/A (P=0.061). However, the funnel plot
did show some asymmetry, subsequently corroborated by Egger’s
test, for comparisons of the EGF 61* G allele and A allele
(P=0.021), G/G and A/A (P=0.019), and G/G and G/A+A/A
(P=0.023) (Table 2).
Discussion
One characteristic of tumors is dysregulation of cell growth.
HCC involves complex, multistep and heterogeneous malignant
tumorigenesis. The pathogenesis of HCC involves host genetic
factors, environmental factors and modulation of molecular
signaling pathways implicated in malignant transformation of
hepatocytes and tumor progression [27]. Cirrhosis associated with
HBV and/or HCV infection and alcohol is the most well
established environmental risk factor for HCC around the world.
In fact, cirrhosis is considered a precancerous stage to some extent,
although only a fraction of cirrhosis patients and HCV-infected
individuals develop HCC later in life [28]. Moreover, some
patients without known risk factors eventually develop HCC [29].
Therefore, genetic predisposition may contribute to the process of
hepatocarcinogenesis.
Many meta-analyses have shown that polymorphism in some
genes strongly correlates with susceptibility to HCC [30–32].
Some studies have reported an association between polymorphism
in EGF 61*A/G and HCC risk [16–17]. The EGF receptor
signaling pathway is thought to be an important mediator of
hepatocyte proliferative capacity and liver regeneration as a result
of chronic liver injury [33]. Dysregulation of the EGF receptor
signaling pathway plays an important role in early hepatocarcin-
ogenesis and other tumorigenesis [34–36]. One mechanism by
which the EGF gene polymorphism may lead to increased risk of
HCC is by modulating EGF levels.
Other studies of the EGF 61*A/G polymorphism and HCC risk
failed to find an association (Table 3). The most likely reason for
the inconsistencies among these studies is that most are single case-
control studies with small sample sizes. To help resolve these
conflicting results using a larger sample size, we conducted meta-
analysis of published studies. Our results for the total population
suggest an increased HCC risk for subjects carrying the EGF
61*G/G genotype, and a protective effect for the A/A genotype.
Our approach also allowed us to look for potential ethnic
differences in the association. Analysis of ethnic subgroups showed
that in the three different groups (Chinese, Caucasian and mixed),
the 61*G allele was highly associated with increased risk of HCC
based on allelic contrast, homozygote comparison and the
recessive genetic model. Our findings are in line with those of a
recently published meta-analysis showing that the EGF 61*G/G
genotype in Caucasians is associated with increased risk of glioma
[37], and recurrence of liver metastases [25].
Our meta-analysis suggests that the EGF 61*A polymorphism
may reduce susceptibility to HCC among Chinese. For mixed or
Caucasian populations, however, our stratified meta-analysis
according to ethnicity failed to demonstrate a statistically
significant protection from HCC associated with the EGF 61*A
homozygous variant genotype. This is most probably because our
meta-analysis involved only two studies with a mixed population
and only one with a Caucasian population. There may be a high
risk of selective bias for the relationship between the EGF 61*G/A
polymorphism and HCC development in these two populations, so
this association should be re-evaluated in studies with large sample
sizes. Therefore, the negative results in the present study should be
interpreted with caution.
All the patients in the hospital-based control populations had
HBV infection and/or cirrhosis. Among these hospital-based
controls, the EGF 61*G allele was statistically associated with
increased risk of HCC based on allelic contrast, homozygote
comparison and the recessive genetic model. In contrast, this
polymorphism was associated with decreased HCC risk in the
dominant genetic model in both the hospital- and population-
based control populations. At the same time, the EGF 61*G allele
was not associated with HCC susceptibility in the population-
based control. The G/G genotype frequency in the case group was
significantly higher than in the control group with HBV infection
and/or cirrhosis, implying that HBV and/or cirrhotic patients
with the G/G genotype may be at higher risk of HCC
development. At the same time, the frequency of the G/G
genotype in healthy individuals (261/514) was similar to that in the
case group (260/521), suggesting that healthy individuals with the
G/G genotype may not be at higher risk of developing HCC. We
infer from these results that environmental factors are more
important than host genetic factors in HCC. In other words,
environmental factors mediate the ability of genetic factors to
contribute to HCC. Our findings suggest that the EGF 61*A/G
Figure 2. Forest plots describing the association of EGF polymorphism 61*A/G with hepatocellular carcinoma. (a) ORs were calculated
by comparing the G/G genotype with the G/A+A/A genotypes. (b) ORs were calculated by comparing the A/A genotype with the G/A+G/G
genotypes.
doi:10.1371/journal.pone.0032159.g002
EGF 61*A/G and HCC Risk
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shown with pseudo 95% confidence limits. S.E., standard error.
doi:10.1371/journal.pone.0032159.g003
Table 2. Publication bias tests for comparisons involving the EGF 61*A/G polymorphism.
Genetic comparison Coefficient Standard error t P value 95% CI of intercept
G-allele vs. A-allele 3.073 0.985 3.12 0.021 0.662 to 5.484
G/G vs. A/A 3.110 0.981 3.17 0.019 0.710 to 5.511
G/G+G/A vs. A/A 22.766 1.199 22.31 0.061 25.700 to 0.168
G/G vs. G/A+A/A 2.889 0.954 3.03 0.023 0.554 to 5.224
doi:10.1371/journal.pone.0032159.t002
EGF 61*A/G and HCC Risk
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background of chronic HBV infection and/or cirrhosis.
Since ethnicities can show different genotype frequencies,
ethnicity should be taken into account in genetic association
studies. Previous studies [19–20] have found the frequency of the
EGF 61*A/A genotype to be approximately 10% in Asians but
approximately 30% in Caucasians. Similarly, the present study
found a higher frequency of the A/A genotype in the mixed and
Caucasian populations than in the Chinese population. The
pooled ORs of this meta-analysis suggest that the EGF 61*G allele
is a risk factor for HCC, while the EGF 61*A allele is a protective
factor. Therefore, differences in the distribution of EGF genotypes
among different ethnicities may help explain the higher HCC
prevalence among Asians [2].
Some limitations of this meta-analysis should be considered
when interpreting the results. One of the major concerns is bias
due to selective publication. Obvious publication bias was detected
in the comparison of G- and A-alleles, G/G and A/A genotypes,
and G/G and G/A+A/A genotypes. Second, bias may result from
the fact that unpublished data, as well as papers published in
languages other than English and Chinese, were not included.
Third, the results may be affected by additional confounding
factors, such as hepatitis B infection status, tumor status, gender or
age, but most studies either did not report these baseline data or
aggregated them in different ways, making it impossible to include
them in the meta-analysis. Fourth, the number of published studies
included in our meta-analysis was not sufficiently large for a
comprehensive analysis. In particular, the subgroup analyses of a
mixed-ethnic population and a Caucasian population were based
on only two and one study, respectively. Fifth, there was significant
heterogeneity among the studies in the different ethnic subgroups.
Sixth, nearly all of the studies were performed in Asian and
Caucasian populations; further studies are needed in other ethnic
groups in order to capture the full range of possible ethnic
differences in EGF polymorphisms.
In conclusion, this meta-analysis suggests that the G-allele of the
EGF 61* polymorphism (rs4444903) is associated with increased
risk of HCC, while the A-allele contributes to decreased
susceptibility to HCC, especially in the Chinese population. These
results suggest that EGF gene variation may play an important
role in the occurrence of HCC. However, since this meta-analysis
included few studies from non-Asian populations, large, well-
designed studies in Caucasian and African-American populations
are warranted to re-evaluate these associations.
This meta-analysis is guided by the PRISMA statement
(Checklist S1).
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